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studies is present and real, we have developed a liquid chromatography
tandem mass spectrometry method in this work for quantitative deter-
mination of MLN0128 in human plasma to support the clinical develop-
ment of the drug. The method developed has been validated according
to the US Food and Drug Administration (US‐FDA, 2001) guidance for
industry on bioanalytical method validation with the intention to be
used for pharmacokinetic study of MLN0128 in clinical trials.
EXPERIMENTAL
Chemicals
MLN0128 {3‐(2‐aminobenzo[d]oxazol‐5‐yl)‐1‐isopropyl‐1H‐pyrazolo
[3,4‐d] pyrimidin‐4‐amine, C15H15N7O} was purchased from
Selleckchem (Houston, TX, USA) (catalog no. S2811, purity >99.64%).
STK040263 {1‐benzyl‐1H‐pyrazolo [3,4‐d]pyrimidin‐4‐amine,
C12H11N5} (as internal standard, IS, purity >90%) was purchased from
Vitas‐M Laboratory (Apeldoorn, Netherlands). LC/MS‐grade methanol
(MeOH), LC/MS‐grade acetonitrile, HPLC‐grade water, HPLC‐grade
methyl tert‐butyl ether (MTBE) and ACS‐grade dimethylsulfoxide were
purchased from Fisher Scientific (Pittsburgh, PA, USA). Ammonium
formate was from Sigma‐Aldrich (St Louis, MO, USA). Blank pooled
human plasma and six individual lots of blank human plasma with
specific lot numbers (IR11–1670, 1M2070–01, 1M2070–02,
1M2070–03, 1M2070–04, 1M2070–05 and 1M2070–06) were
purchased from Innovative Research (Novi, MI, USA).
Instrumentation
The liquid chromatography tandem mass spectrometry (LC–MS/MS)
system used in this work consisted of a Shimadzu (Columbia, MD,
USA) Prominence UFLC unit with a controller (CBM‐20 A), two binary
pumps (LC‐20AD) and an autosampler (SIL‐ 20 AC), and an AB Sciex
(Foster City, CA, USA) API3200 turbo‐ion‐spray® triple quadruple
tandem mass spectrometer equipped with an electrospray ionization
(ESI) probe and a syringe pump. The LC–MS/MS system was
controlled by AB Sciex Analyst® (version 1.5.1) software for its
operation, data acquisition and processing.
Liquid chromatography
Chromatographic separation of MLN0128 and the IS was carried out
isocratically at room temperature on a Waters (Milford, MA, USA)
XTerra® MS C18 column (2.1 × 50mm, 3.5 μm) connected to a Waters
XTerra® MS C18 guard column (2.1 × 10mm, 3.5 μm) with mobile
phase consisting of methanol–acetonitrile–ammonium formate
(10.0mM, pH 2.8; 34:6:60, v/v/v) pumped at a flow rate of
0.300mLmin 1. Acetonitrile was used as the wash solvent between
injections. For each analysis, 10.0 μL of sample was injected into the
system by autosampler set at 4°C, and the total run time was 4min.
Tandem mass spectrometry
Mass spectrometric detection was carried out using positive
electrospray ionization (ESI+) mode, which was tuned for compound‐
dependent and source‐dependent parameters by separate infusion of
MLN0128 (500 ngmL 1) and IS (500 ngmL 1) in the mobile phase by
the syringe pump at a flow rate of 10 μLmin 1. The optimized param-
eters were as follows: curtain gas at 45 psi; collision gas at 3 psi; ion
spray voltage at 5500 V; temperature at 600°C; ion source gas 1 at
55 psi; ion source gas 2 at 45 psi; declustering potential at 60 V;
entrance potential at 7.5 V; collision energy at 35 eV; collision cell exit
potential at 4 V; and resolution at 0.7 units. Quantitation of MLN0128
and IS was done in multiple‐reaction‐monitoring (MRM) mode with the
mass transitions, m/z 310→ 268 for MLN0128, and m/z 226→ 127
for the IS, respectively, using a dwell time of 400ms for each analyte.
Preparation of stock and working solutions
The stock solutions of MLN0128 (1.00mgmL 1) and IS (1.00mgmL 1)
were prepared as follows: MLN0128 and the IS (1mg or more) were
weighed out precisely on a Mettler Toledo (Greifensee, Switzerland)
XS20 model analytical balance to 0.01mg, and each standard com-
pound dissolved in an appropriate volume of dimethylsulfoxide to
make a concentration of 1.00mgmL 1. These stock solutions were
kept in a freezer at −20°C before use. The working solutions of
MLN0128 (1.00 μgmL 1) and the IS (1.00 μgmL 1) were freshly pre-
pared by serial dilution of each stock solution with the mobile phase.
The stock solution of ammonium formate (0.100M) was prepared
by dissolving appropriate amount of ammonium formate salt in a
known volume of HPLC‐grade water and stored in a refrigerator at
4°C before use. The working solution of ammonium formate
(10.0mM) was prepared by a 10‐fold dilution of the stock solution with
HPLC‐grade water and adjusted to pH 2.8 using formic acid, if
necessary.
Preparation of standard solutions
The standard solutions of MLN0128 (1.00, 2.00, 2.50, 5.00, 10.0, 25.0,
30.0, 50.0, 100, 200, 250, 300, 400 and 500 ngmL 1) were prepared
daily by sequential dilution of the working solution with the mobile
phase to make higher concentrations of the standard solutions
(e.g. 100, 200, 250, 300, 400 and 500 ngmL 1) and by serial dilutions
of these standard solutions with the mobile phase to make lower
concentrations of the standard solutions (e.g. 1.00, 2.00, 2.50, 5.00,
10.0, 25.0, 30.0 and 50.0 ngmL 1). The standard solution of the IS at
concentration of 50 ngmL 1 was prepared freshly by direct dilution
of working solution of the IS with the mobile phase.
Preparation of plasma calibrators and quality
controls
Plasma MLN0128 calibrators (0.100, 0.200, 0.500, 1.00, 2.50, 5.00,
10.0, 25.0 and 50.0 ngmL 1) were prepared by mixing 10.0 μL of each
MLN0128 standard solution (1.00, 2.00, 5.00, 10.0, 25.0, 50.0, 100,
250 and 500 ngmL 1) with 90.0 μL of blank pooled human plasma.
The zero calibrator (or single blank plasma) was prepared by mixing
10.0 μL of the mobile phase with 90.0 μL of blank pooled human
plasma. Plasma MLN0128 quality controls (QCs) (0.25, 3.00 and
40.0 ngmL 1) were prepared by mixing 10.0 μL of each MLN0128
standard solution (2.50, 30.0 and 400 ngmL 1) with 90.0 μL of blank
pooled human plasma. The plasma MLN0128 calibrators and QCs
were stored at −20°C before use.
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Plasma sample preparation
Plasma samples (e.g. calibrator and QC) were thawed to room temper-
ature and placed in disposable borosilicate glass tubes (13 × 100mm)
from VWR (Radnor, PA, USA). For each 100 μL of plasma sample,
10.0 μL of the IS (50.0 ngmL 1) were added except the double blank
plasma where 10.0 μL of the mobile phase were added. After vortexing
for 30 s, 2mL of MTBE were added to the sample tube, and the liquid
phases were mixed in a multi‐tube vortex mixer (Troemner, Thorofare,
NJ, USA) for 5min to extract the analytes, then centrifuged in a Sorvall
ST40R centrifuge (Thermo Scientific, Waltham, MA, USA) at 4816 × g
at 4°C for 8min. The organic phase (upper layer) was transferred into
a fresh borosilicate glass tube and dried in a TurboVap® LV evaporator
(Caliper Life Sciences, Hopkinton, MA, USA) at 30°C under nitrogen
gas at a pressure of 20 psi for 12min. The resultant dried residue
was reconstituted in 100 μL of a reconstitution solution containing
methanol and 10mM ammonium formate (pH 2.8) (1:9, v/v) for the
subsequent LC–MS/MS analysis.
Method validation
The method developed was validated in human plasma following the
US Food and Drug Administration guidance for industry on
bioanalytical method validation in terms of selectivity, lower limit of
quantitation, matrix effect, recovery, linear calibration range, accuracy
and precision, as well as stabilities for short‐term sample processing
and long‐term sample storage.
Selectivity and lower limit of quantitation
The selectivity of this method was assessed by any interferents
observed at the retention times and mass transitions of MLN0128
and the IS in six individual blank human plasma and blank pooled
human plasma matrices. The lower limit of quantitation (LLOQ) of
the method was defined as the lowest concentration of MLN0128
plasma calibrator with accuracy expressed as percent relative error
(RE) and precision expressed as percentage coefficient of variation
(CV) at ≤ ± 20 and ≤20%, which was validated in six individual and
pooled human plasma matrices.
Matrix factor and recovery
The absolute matrix factor (MF) of MLN0128 (or the IS) was deter-
mined by the mean peak area of MLN0128 (or the IS) at a specified
concentration in the extracted plasma matrix over that of MLN0128
(or the IS) at the concentration in the reconstitution solution. The IS
normalized MF was determined by the absolute MF of MLN0128 over
that of the IS. For this study, MLN0128 QCs at three concentrations
(0.250, 3.00 and 40.0 ngmL 1) with a fixed concentration of the IS
(5.00 ngmL 1) were prepared in six individual extracted plasma
matrices and in the reconstitution solution.
The absolute recovery of MLN0128 (or the IS) was determined by
the mean peak area of MLN0128 (or the IS) at a specific concentration
in plasma matrix over that of MLN0128 (or the IS) at the concentration
in the extracted plasma matrix multiplying by 100%. The IS normalized
recovery was determined by the absolute recovery of MLN0128 over
that of the IS multiplying by 100%. For this study, MLN0128 QCs at
three concentrations (0.250, 3.00 and 40.0 ngmL 1) with a fixed
concentration of the IS (5.00 ngmL 1) were prepared in the pooled
and the extracted pooled human plasma matrices.
Linear calibration curve
MLN0128 calibration curve was constructed using nine non‐zero
plasma calibrators, one single‐blank (with the IS only), and one
double‐blank plasma (without MLN0128 or the IS). The concentrations
of non‐zero calibrators were 0.100, 0.200, 0.500, 1.00, 2.50, 5.00,
10.0, 25.0 and 50.0 ngmL 1 with the IS concentration of 5.00 ngmL 1.
The peak area ratios of MLN0128 to the IS (y) were plotted vs
the concentrations of MLN0128 plasma calibrators (x) with 1/x
weighting.
Accuracy, precision and dilution study
In this work, the intra‐assay accuracy and precision were determined
using five replicate injections of QC samples at three different
concentrations (0.250, 3.00 and 40.0 ngmL 1). The inter‐assay
accuracy and precision were determined using five parallel injections
from five identical QCs at three different concentrations (0.250, 3.00
and 40.0 ngmL 1) in three separate days. Dilution study was
conducted using QC concentration at 250 ngmL 1, which was 5 times
beyond the upper limit of the linear calibration curve (50 ngmL 1), and
the analysis was carried out after 10‐fold dilution of plasma dilution
QC by the pooled blank human plasma.
Stability studies
The stabilities of the MLN0128 stock solution (1.00mgmL 1) and
plasma QCs (0.250 and 40.0 ngmL 1) were investigated against test
controls at the same concentrations prepared freshly on the day of
the experiment. The stability of MLN0128 was determined from five
replicates by comparing the mean‐peak‐area ratio of MLN0128 to
the IS in a test sample with that of the test control, and multiplying
by 100%.
In the stability studies, the stock solution was kept on bench‐top
(23°C) for 6 and 24 h before dilution to 1.00 and 50.0 ngmL 1. The
QCs were kept on the bench‐top (23°C) before sample preparation
or in an autosampler (4°C) after sample preparation for 6 and 24 h.
For the freeze–thaw study, the QCs were subjected to three freeze–
thaw cycles where the samples were frozen at −20°C for at least
24 h and thawed at room temperature (23°C) unassisted. For long‐
term storage study, the QCs were stored at −20°C and tested up to
2months. For the above studies, the working solution of the IS
(50.0 ngmL 1) was prepared freshly on the day of experiment, and
added to each sample prior to sample extraction.
RESULTS AND DISCUSSION
Method development
Internal standard (IS)
Owing to the lack of a heavy stable isotope of MLN0128,
several commercially available structural analogs such as PP2
(Sigma Aldrich, MO, USA), STK040263 and STK560245 (Vitas‐M
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Laboratory, Apeldoorn, Netherlands) were acquired and evaluated
as an IS for quantitation of MLN0128. STK040263 was chosen
for the subsequent work because it was rapidly and efficiently
separated from MLN0128 by isocratic elution, whereas the
other structural analogs needed gradient elution to achieve the
similar result.
Chemical properties of the analyte and the IS
Both MLN0128 and STK040263 are small, weak basic, organic mole-
cules with monoisotopic masses of 309 and 225 g/mol (Figure 1).
The logP and pKa (of conjugate acid) of these compounds calculated
by the ACD/Labs® software version 11.02 (Advanced Chemistry
Development, Inc., Toronto, Ontario, Canada) are 2.35 and 3.77 for
MLN0128, and 1.36 and 4.20 for STK040263, respectively. The
logP values reveal the hydrophobic nature of these compounds,
whereas the pKa values of the conjugate acids suggest that the amino
groups of these compounds are protonated at low pH values. These
chemical properties of the analyte and the IS guided us in the
selections of solvent, mobile phase and chromatographic column.
Mass spectrometric detection
In this work, a triple quadrupole tandem mass spectrometer (MS/MS)
was used for analyte detection owing to its high selectivity and low
limit of detection. Since MLN0128 and the IS were readily protonated
in the acidicmobile phase (pH 2.8), positive electrospray ionization (ESI+)
was chosen as a means of sample introduction. As shown in Figure 1,
MLN0128 and the IS readily produced protonated molecules
[MLN0128 +H]+ at m/z 310 (Figure 1a) and [IS + H]+ at m/z 226
(Figure 1b) in the ionization chamber of the mass spectrometer, and
these precursor ions were further fragmented in the collision cell into
predominant product ions at m/z 268 for MLN0128 and at m/z 127
for the IS. These predominant product ions were further confirmed
using an Agilent 6540 UHD Accurate‐Mass Q‐TOF LC/MS system
(Agilent Technologies, Santa Clara, CA, USA) (data not shown), and
the chemical structures of these ions were postulated (Figure 1a and b)
with the aid of Agilent Molecular Formula Generator and Molecular
Structure Coordinator software. In the case of product ion of the IS
(m/z 127), there was no structure suggested by the software; the
postulated structure was hypothesized based on the chemical structure
of the precursor ion and the found fragment formula (C10H7
+) of the
product ion. MRM mode was adopted for quantitation of MLN0128
with the mass transitions of m/z 310→ 268 for MLN0128 and m/z
226→ 127 for the IS, respectively.
Liquid chromatographic separation
Owing to the hydrophobic nature of MLN0128 and STK040263,
reversed‐phase chromatographic columns were considered for analyt-
ical separation. Several columns including Waters MS® XTerra C18,
Waters MS XTerra® C8 andWaters Atlantis® T3 (Waters Corporation,
Milford, MA, USA) were tested. Among them, the Waters XTerra® MS
C18 column was chosen because it exhibited more symmetrical and
sharper peaks with improved resolution and signal‐to‐noise ratio in
comparison to the others.
Because both MLN0128 and STK040263 are amine derivatives,
they have tendency to adsorb on the silica solid support. The use of
ammonium formate (10.0mM at pH 2.8) as a component of the mobile
phase not only promotes the formation of protonated analytes, but
also dynamically competes with the analyte and the IS to prevent
FIGURE 1 The mass spectra of precursor and product ions of MLN0128 and STK040263. Experimental conditions were the same as those
described in the section ‘Tandem mass spectrometry’
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chemical tailing on the column (Hansen, Helboa, & Lund, 1984;
McDowall, Pearce, & Murkitt, 1989). Furthermore, for achieving a
proper solvent strength and selectivity, a mixture of methanol and
acetonitrile at a ratio of 85:15 (v/v) was used as another component
of the mobile phase for rapid and efficient separation of the analyte
and the IS.
For this work, the optimized liquid chromatographic separation
was obtained using a Waters XTerra® MS C18 column, and a
mobile phase consisting 60% of ammonium formate (10.0mM,
pH 2.8) and 40% methanol–acetonitrile (85/15, v/v) pumped at a
flow rate of 0.300mLmin 1. The total run time was 4.00min
with retention times of 1.95 and 2.94min for the IS and MLN0128,
respectively (Figure 2).
Plasma sample preparation
Both protein precipitation and liquid–liquid extraction (LLE) were
investigated as plasma sample preparation methods in this work. Even
though protein precipitation was simpler to do, but it gave a lower ana-
lyte recovery and stronger matrix effect in comparison to LLE (data not
shown).
For the LLE study, several organic solvents such as MTBE, ethyl
acetate, isopropanol and hexane were investigated as extraction
solvents for plasma sample either alone or in combination. While
MTBE showed the highest extraction efficiency, hexane yielded
none. Therefore, MTBE was chosen as the organic solvent for the
sample preparation by LLE. Figure 3 shows the matrix effect of
the MTBE‐extracted blank plasma injected by the autosampler on
FIGURE 2 The mass chromatograms of
MLN0128 and IS in human plasma. (a) double
blank plasma (with neither MLN0128 nor IS);
(b) single blank plasma (with IS only at
50.0 ngmL 1); and (c) at LLOQ (MLN0128 at
0.100 ngmL 1 and IS at 50.0 ngmL 1). Experi-
mental conditions were the same as those
described in the sections ‘Liquid chromatog-
raphy’ and ‘Tandem mass spectrometry’
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the analytical signal of analyte standard solution (i.e. the baseline
signal) via post‐column infusion, which revealed that the matrix effect
(i.e. signal elevation or suppression) mainly occurred in the retention
times between 0.80 and 1.50min, and did not affect the analytical
signals of the IS and MLN0128 at the peak values of 1.95 and
2.94min, respectively.
Reconstitution solution
During plasma sample preparation, MTBE extract containing
the analyte and the IS was dried under nitrogen gas, and the
resultant residue was reconstituted in a reconstitution solution
for the subsequent LC–MS/MS analysis. For this work, the
mobile phase was initially used as the reconstitution solution to
reconstitute the dried residue; however, it produced a cloudy
solution (colloidal suspension) and caused injection problems. In an
attempt to remove the cloudiness of the reconstitute, various ratio
of acetonitrile–methanol as the organic components of the mobile
phase, and various buffer compositions (e.g. ammonium formate,
ammonium acetate or ammonium bicarbonate) and concentrations
(e.g. 5.00–20.0mM) as the aqueous component of the mobile
phase were tested, and showed no change on the cloudiness of the
reconstitute. Eventually, the use of lower percentage of organic
solvent in reconstitution solution [i.e. 10% MeOH with 90%
ammonium formate solution (10mM, pH 2.8)] resulted in clear sample
solution. Therefore, 10% MeOH with 90% ammonium formate
solution (10mM, pH 2.8) was chosen as the reconstitution solution of
the subsequent work.
Method validation
Selectivity and LLOQ
The selectivity and the LLOQ of the method were examined in this
work. As illustrated by the representative mass chromatograms of
the double blank plasma (Figure 2a) recorded at the same mass
transitions of MLN0128 and the IS, while no detectable interference
was observed at the same retention time of IS, a tiny endogenous
interferent peak was detected near the retention time of MLN0128.
The representative mass chromatograms of the single blank plasma
(Figure 2b) showed that the interferent was not a part of the IS. Since
the mean peak area of the endogenous interferent from six different
individual double blank plasmas was <6% of that of MLN0128 at the
LLOQ (Figure 2c), which was much lower than the limit set by US Food
and Drug Administration (≤20%), the interferent was tolerated at the
LLOQ in this method. The LLOQ of this method was 0.100 ngmL 1
for MLN0128, which had accuracy and precision ≤ ± 9 and ≤7%
(Table 1), assessed by five replicate measurements of six plasma cali-
brators at LLOQ each prepared by a different individual blank plasma.
Matrix effect and recovery
Matrix effect was assessed by the MF of MLN0128 at three QC con-
centrations in six individual plasma matrices. As shown in Table 2,
FIGURE 3 The mass chromatograms of post‐
column infusion of MLN0128. (a) injection of
10.0 μL mobile phase; and (b) injection of
10.0 μL MTBE extract of blank human plasma.
The LC–MS conditions were the same as
those in Figure 2, and the post‐column infu-
sion of MLN0128 (500 ngmL 1) was carried
out by an integrated syringe pump through a
three‐port mixing tee at a flow rate of
10.0 μLmin 1
TABLE 1 Accuracy and precision of MLN0128 at LLOQ in six individual lots of human plasma (n = 5)
Plasma matrix Nominal [MLN0128] (ng mL−1) Mean measured [MLN0128] (ng mL−1) SD (ngmL−1) Precision (CV, %)a Accuracy (RE, %)b
Lot 1 0.100 0.104 0.001 1 4
Lot 2 0.100 0.101 0.004 4 1
Lot 3 0.100 0.093 0.003 3 −7
Lot 4 0.100 0.102 0.007 7 2
Lot 5 0.100 0.096 0.003 3 −4
Lot 6 0.100 0.109 0.003 3 9
aCV (Standard deviation/mean) × 100%.
bRE [(measured nominal)/(nominal)] × 100%.
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the absolute MFs of MLN0128 and the IS were 0.93–1.04 and
0.91–1.03, respectively, and the IS normalized MFs were 0.96–1.08.
These data revealed that the matrix effect of human plasma was
negligible in the measurements of MLN0128 and the IS when MTBE
was used as organic solvent for the analyte extraction.
The recoveries of MLN0128 at three different QC concentrations
in pooled human plasma are summarized in Table 3. The
absolute recoveries of MLN0128 and the IS were 79–84 and
81–84%, respectively, and the IS normalized recoveries were
95–100%. These results indicated that MTBE extraction used was
efficient and consistent for the recovery of MLN0128 and the IS
from human plasma samples.
Calibration curve
The mean linear regression equation based on three individual calibra-
tion curves in three days was y = 0.516 (±0.005)x + 0.015 (±0.004) over
the range of 0.100–50.0 ngmL 1 with a correlation coefficient of
0.999. As shown in Table 4, the accuracy and precision of individual
plasma calibrators were ≤ ± 6% and ≤7%, respectively.
Assay accuracy, precision and dilution integrity
As shown in Table 5, the intra‐assay accuracy and precision were ≤ ± 4
and ≤8%, and the inter‐assay accuracy and precision were ≤ ± 4 and
≤2%, respectively, indicating that the method developed was accurate
and precise. The dilution studies showed that the intra‐assay accuracy
and precision were ≤ ± 3 and ≤3%, and the inter‐assay accuracy and
precision were ≤ ± 1 and ≤1%, indicating the integrity of plasma sam-
ples could be preserved in sample dilution.
Stability studies of MLN0128
The stability studies for MLN0128 were conducted and the data are
summarized in Table 6. The stock solutions and plasma QCs were
found to be stable by free standing on bench‐top at room temperature
TABLE 2 Matrix factors of MLN0128 QCs in six individual lots of
human plasma (n = 5)
Plasma
matrix
[MLN0128]
(ng mL−1)
MFMLN0128
± SDa MFIS ± SD
b
IS normalized
MF ± SDc
Lot 1 0.250 1.02 ± 0.02 0.94 ± 0.02 1.08 ± 0.04
3.00 1.02 ± 0.03 0.95 ± 0.01 1.07 ± 0.02
40.0 0.99 ± 0.02 0.96 ± 0.01 1.04 ± 0.02
Lot 2 0.250 0.96 ± 0.03 0.91 ± 0.02 1.05 ± 0.05
3.00 1.00 ± 0.02 0.98 ± 0.01 1.02 ± 0.03
40.0 0.98 ± 0.01 0.98 ± 0.01 1.00 ± 0.02
Lot 3 0.250 0.98 ± 0.06 1.00 ± 0.01 0.98 ± 0.05
3.00 0.99 ± 0.01 0.98 ± 0.01 1.01 ± 0.02
40.0 0.93 ± 0.01 0.97 ± 0.01 0.96 ± 0.01
Lot 4 0.250 1.04 ± 0.06 1.02 ± 0.01 1.01 ± 0.06
3.00 1.01 ± 0.01 1.00 ± 0.01 1.01 ± 0.01
40.0 0.96 ± 0.01 0.95 ± 0.02 1.01 ± 0.01
Lot 5 0.250 0.99 ± 0.04 0.99 ± 0.00 1.00 ± 0.04
3.00 0.99 ± 0.01 0.97 ± 0.02 1.02 ± 0.01
40.0 0.97 ± 0.01 0.95 ± 0.01 1.02 ± 0.02
Lot 6 0.250 1.0 ± 0.1 1.03 ± 0.01 1.0 ± 0.1
3.00 0.98 ± 0.02 0.96 ± 0.03 1.02 ± 0.02
40.0 0.94 ± 0.02 0.92 ± 0.03 1.02 ± 0.02
aMFMLN0128 (mean peak area of MLN0128 in the extracted plasma
matrix)/(mean peak area of MLN0128 in the reconstitution solution).
bMFIS (mean peak area of the IS in the extracted plasma matrix)/(mean
peak area of the IS in the reconstitution solution).
cIS normalized MF MFMLN0128/MFIS.
TABLE 4 Accuracy and precision of plasma MLN0128 calibrators in three validation batches over three different days
Nominal [MLN0128] (ng mL−1) Measured [MLN0128] (ngmL−1) SD (ng mL−1) Precision (CV, %) Accuracy (RE, %)
0.100 0.101 0.008 7 0.6
0.200 0.203 0.006 3 1
0.500 0.49 0.02 3 −1
1.00 0.978 0.006 0.6 −2
2.50 2.5 0.1 3 1
5.00 4.89 0.04 0.6 −2
10.0 9.9 0.3 2 −1
25.0 26.4 0.5 2 6
50.0 48.8 0.7 1 −2
TABLE 3 Recovery of MLN0128 in pooled human plasma (n = 5)
[MLN0128] (ng mL−1) RecoveryMLN0128
a ± SD (%) RecoveryIS
b ± SD (%) IS Normalized recoveryc ± SD (%)
0.250 84 ± 3 84 ± 1 100 ± 3
3.00 80 ± 2 84 ± 3 95 ± 3
40.0 79 ± 1 81 ± 2 98 ± 1
aRecoveryMLN0128 [(mean peak area of MLN0128 in plasma matrix)/(mean peak area of MLN0128 in extracted plasma matrix)] × 100%.
bRecoveryIS [(mean peak area of IS in plasma matrix)/(mean peak area of IS in extracted plasma matrix)] × 100%.
cIS normalized recovery [(RecoveryMLN0128)/(RecoveryIS)] × 100%.
PA mean peak area.
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for at least 24 h prior to sample preparation with recoveries of 99–101
and 94–105%, respectively. The plasma QCs were also stable for at
least 24 h in autosampler set at 4°C post sample preparation with
recoveries of 91–104%. The recoveries of plasma QCs after three
freeze–thaw cycles were 92–102%, and after long‐term (2months)
storage at −20°C recoveries were 95–101%. These studies showed
that there were no significant losses of MLN0128 under the test
conditions.
Method application
The method developed was intend to support the proposed
clinical studies of MLN0128 in a ‘Randomized Pilot Phase 0 and
FLT‐PET/MRI Imaging Biomarker Study of MLN0128 in Recurrent
Glioblastoma Multiforme’ and a ‘Phase 1 Study of MLN0128
with Bevacizumab’ from the Case Comprehensive Cancer Center in
response to the NCI/CTEP solicitation in 2013. Even though both
proposals were not funded eventually, the validated method may
be used by the scientific community for preclinical and clinical studies
of MLN0128.
CONCLUSIONS
A rapid and selective LC–MS/MS method has been developed for the
quantitative determination of MLN0128 in human plasma. In this
method, MLN0128 and the IS were extracted from human plasma by
an LLE procedure, and separated by reversed‐phase chromatography
with isocratic elution. Quantitation of MLN0128 was carried out by
internal calibration and positive electrospray ionization tandem mass
spectrometry operated in MRMmode. This method has been validated
according to US Food and Drug Administration guidance for industry
on bioanalytical method validation. It may be used in clinical studies
of MLN0128 in human.
TABLE 5 Intra‐ and inter‐assay accuracy and precision of MLN0128 in pooled human plasma (n = 5)
Nominal [MLN0128] (ng mL−1) Measured [MLN0128] (ngmL−1) SD (ng mL−1) CV, % RE, %
Intra‐assaya
0.250 0.249 0.007 3 −0.6
3.00 2.94 0.03 1 −2
40.0 38 3 8 −4
250c 257 7 3 3
Inter‐assayb
0.250 0.243 0.005 2 −3
3.00 2.88 0.05 2 −4
40.0 38.3 0.6 1 −4
250c 253 4 1 1
aMeasured by five replicate measurements of each QC sample within a validation batch.
bMeasured by five parallel measurements of five identical QC samples at each concentration over three validation batches.
cDilution QC was measured after a 10‐fold dilution with pooled blank human plasma and the reported concentration was back calculated by multiplying a
factor of 10.
TABLE 6 Stabilities of MLN0128 under various test conditions (n = 5)
Test conditions Temperature (°C) MLN0128
Recovery ± SD (%)
6 h 24 h
Bench‐top 23 Stock solutiona 100 ± 1 101 ± 1
Stock solutionb 101 ± 1 99 ± 1
Bench‐top 23 Low QCc 98 ± 4 105 ± 5
High QCc 94 ± 1 97 ± 2
Autosampler 4 Low QC 94 ± 3 104 ± 2
High QC 93 ± 1 91 ± 1
Three freeze thaw cycles −20 23 Low QC 102 ± 2 94 ± 1
High QC 99 ± 1 92 ± 1
Long term (60 days) −20 Low QC 101 ± 1
High QC 95 ± 1
aThe concentration of MLN0128 stock solution was 1.00 mgmL 1, which was measured by serial dilution to 1.00 ngmL 1 in mobile phase.
bThe concentration of MLN0128 stock solution was 1.00 mgmL 1, which was measured by serial dilution to 50.0 ng mL 1 in mobile phase.
cThe concentration of plasma low and high QCs were 0.250 and 40.0 ng mL 1, respectively.
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